Abstract Number: 2669 • 2019 ACR/ARP Annual Meeting
Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Background/Purpose: To investigate survival trends in patients with giant cell arteritis (GCA) diagnosed over a 60-year period.Methods: We assembled a population-based incidence cohort of patients…Abstract Number: 2670 • 2019 ACR/ARP Annual Meeting
Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that primarily affects the aorta and its branches. Extracranial branches of the carotid artery are…Abstract Number: 2671 • 2019 ACR/ARP Annual Meeting
PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Background/Purpose: PET/CT is a useful modality to diagnose GCA but there is limited knowledge as to how inflammatory vascular findings evolve on follow-up scans. This…Abstract Number: 2672 • 2019 ACR/ARP Annual Meeting
Ultrasonography in the Diagnosis of Giant Cell Arteritis
Background/Purpose: Imaging has been recently recognized as a tool equivalent to the temporal artery biopsy in diagnosing giant cell arteritis (GCA). Amongst a variety of…Abstract Number: 2673 • 2019 ACR/ARP Annual Meeting
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Background/Purpose: We have few real-world data on the natural history and care of patients with giant cell arteritis (GCA). The objective of this observational study…Abstract Number: 2674 • 2019 ACR/ARP Annual Meeting
Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis
Background/Purpose: Takayasu’s arteritis (TAK) and giant cell arteritis (GCA) are the two major forms of large vessel vasculitis. The study objectives were to compare clinical…Abstract Number: 2675 • 2019 ACR/ARP Annual Meeting
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Background/Purpose: Oral glucocorticoids (OGC) have been the mainstay of treatment for giant cell arteritis (GCA). However, OGCs are associated with several adverse events (AEs). The…Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…Abstract Number: 2677 • 2019 ACR/ARP Annual Meeting
Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Background/Purpose: To study the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the background population in southern Sweden.Methods: The study…Abstract Number: 2678 • 2019 ACR/ARP Annual Meeting
Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms
Background/Purpose: In Giant Cell Arteritis (GCA) two dominant cytokine clusters have been linked to disease activity, IL-6 – IL-17 axis (Th17) and IL-12 – IFN…Abstract Number: 2679 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Background/Purpose: Recently, based on the GiACTA trial results, weekly subcutaneous Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It has…Abstract Number: 2680 • 2019 ACR/ARP Annual Meeting
Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
Background/Purpose: Tocilizumab (TCZ) is the only biological agent approved in Giant Cell Arteritis (GCA). There is general agreement on the initial and the standard maintenance…Abstract Number: 2681 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Background/Purpose: Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It showed to be effective to induce remission, prevent relapses and…Abstract Number: 2682 • 2019 ACR/ARP Annual Meeting
Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution
Background/Purpose: Tocilizumab (TCZ) has proved to be effective in the management of Giant Cell Arteritis (GCA). Based on results of the GiACTA trial, it has…Abstract Number: 2683 • 2019 ACR/ARP Annual Meeting
Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis
Background/Purpose: Assessing cranial artery inflammation plays an important role in the diagnosis of cranial giant cell arteritis (GCA). Although an established tool for assessing large…
